The Impact of lncRNA on Diabetic Kidney Disease: Systematic Review and In Silico Analyses. (27th April 2022)

• Record Type: Journal Article
• Authors: Zhao, Yunyun; Yan, Guanchi; Mi, Jia; Wang, Guoqiang; Yu, Miao; Jin, Di; Tong, Xiaolin; Wang, Xiuge
• Other Names: Asghar Muhammad Zubair Academic Editor.
• Is Part Of: Computational intelligence and neuroscience. Volume 2022(2022)
• Publication Date: 2022-04-27
• Subjects: Neurosciences -- Data processing -- Periodicals; Computational intelligence -- Periodicals; Computational neuroscience -- Periodicals; 612.80285
• DOI: 10.1155/2022/8400106
• Languages: English
• ISSNs: 1687-5265

Abstract

Abstract : Background . Long noncoding RNA (lncRNA) is involved in the occurrence and development of diabetic kidney disease (DKD). It is necessary to identify the expression of lncRNA from DKD patients through systematic reviews, and then carry out silico analyses to recognize the dysregulated lncRNA and their associated pathways. Methods . The study searched Pubmed, Embase, Cochrane Library, WanFang, VIP, CNKI, and CBM to find lncRNA studies on DKD published before March 1, 2021. Systematic review of the literature on this topic was conducted to determine the expression of lncRNA in DKD and non-DKD controls. For the dysregulated lncRNA in DKD patients, silico analysis was performed, and lncRNA2Target v2.0 and starBase were used to search for potential target genes of lncRNA. The Encyclopedia of Genomics (KEGG) pathway enrichment analysis was performed to better identify dysregulated lncRNAs in DKD and determine the associated signal pathways. Results . According to the inclusion and exclusion criteria, 28 publications meeting the eligibility criteria were included in the systematic evaluation. A total of 3, 394 patients were enrolled in this study, including 1, 238 patients in DKD group, and 1, 223 diabetic patients, and 933 healthy adults in control group. Compared with the control, there were eight lncRNA disorders in DKD patients (MALAT1, GAS5, MIAT, CASC2, NEAT1, NR_033515, ARAP1-AS2, and ARAP1-AS1). In addition, five lncRNAs (MALAT1, GAS5, MIAT, CASC2, and NEAT1) participated in disease-related signal pathways, indicating their role in DKD. Discussion . This study showed that there were eight lncRNAs in DKD that were persistently dysregulated, especially five lncRNAs which were closely related to the disease. Although systematic review included 28 studies that analyzed the expression of lncRNA in DKD-related tissues, the potential of these dysregulated lncRNAs as biomarkers or therapeutic targets for DKD remains to be further explored. Trial registration. PROSPERO (CRD42021248634).